Eloralintide sodium
Based on 1 Customer Validation
Eloralintide sodium is an Amylin Receptor agonist. Eloralintide sodium selectively activates AMY1R and AMY3R in cells expressing human or rat AMY1R, AMY3R or CTR. Eloralintide sodium activates AMYRs and CTR in rats, inducing a sustained decrease in plasma Ca2+ levels. Eloralintide sodium reduces appetite and body weight in both lean and obese rats. Eloralintide sodium can be used for research related to obesity.
For research use only. We do not sell to patients.
- Purity : 99.92%
- Formula: C201H319N49O65S2.xNa
- Molecular Weight:4526.10 (free base)
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
All Calcium Channel Isoforms
More
Biological Activity
Description
In Vitro
Eloralintide selectively activates AMY1R and AMY3R in UMUC3 cells expressing human or rat AMY1R, AMY3R or CTR, with an EC50 of 23.9 pM and a Ki of 478.1 pM for human AMY1R, an EC50 of 5.4 pM and a Ki of 48.1 pM for rat AMY1R, as well as an EC50 of 13.8 pM and a Ki of 161.0 pM for rat AMY3R[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
In Vivo
Eloralintide sodium (0.1-300 nmol/kg; s.c.; single dose) reduces food intake and body weight in lean rats, attenuates the induced conditioned taste aversion, and has an ED50 of 8.9 nmol/kg for reducing sweetener preference[3].
Eloralintide sodium (0.1-100 nmol/kg; s.c.; once every three days; 13 days) reduces food intake and body weight in male DIO rats by decreasing fat mass[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rat[1]
-
Dosage:10 or 30 nmol/kg
-
Administration:s.c.; single dose
-
Result:Induced a prolonged decrease in Ca2+ plasma levels.
-
Animal Model:Sprague-Dawley Rats (male, lean)[3]
-
Dosage:0.1, 0.3, 1, 30, 100, 300 nmol/kg
-
Administration:s.c.; single dose
-
Result:Dose-dependently reduced food intake and body
weight, with an ED50 of 3.7 nmol/kg for 96-hour food intake reduction and a 14.9% body weight reduction at the 300 nmol/kg single dose.
Attenuated the induced conditioned taste avoidance.
Reached an ED50 of 8.9 nmol/kg for saccharin preference reduction.
-
Animal Model:Long Evans DIO SD Rat (male, diet-induced obese)[3]
-
Dosage:0.1, 0.3, 1, 30, 100 nmol/kg
-
Administration:s.c.; every three days; 13 days
-
Result:Reduced food intake and body weight in a dose-dependent manner.
Reached an ED50 of 3.7 nmol/kg for change from baseline in food intake at 96 h.
Reached an ED50 of 6.1 nmol/kg for change from baseline in body weight at 96 h.
Resulted in fat mass loss accounting for approximately 85%, 77%, and 68% of total body weight loss at doses of 10, 30, and 100 nmol/kg Q3D, respectively.\nReached an ED50 of 0.8 nmol/kg for loss of fat mass.
Chemical Information
-
Appearance Solid
-
Molecular Weight 4526.10 (free base)
-
Formula C201H319N49O65S2.xNa
-
Color White to off-white
-
Synonyms
LY-3841136 sodium
-
Sequence
{γGlu}-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gly-{Orn}-Leu-Ala-Glu-{(α-Me-Phe)}-Leu-Val-Arg-Ser-Ser-Asn-{(N-Me-Asn)}-Phe-Gly-Pro-{Lys(γGlu-γGlu-C20 diacid)}-Leu-Pro-Pro-Thr-Glu-Val-Gly-Ser-Asn-Thr-Tyr-NH2 (Methylene bridge: Cys2-Cys7)
-
Sequence Shortening
{γGlu}-CNTATCATG-{Orn}-LAE-{(α-Me-Phe)}-LVRSSN-{(N-Me-Asn)}-FGP-{Lys(γGlu-γGlu-C20 diacid)}-LPPTEVGSNTY-NH2 (Methylene bridge: Cys2-Cys7)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
In Vitro:
H2O : 100 mg/mL (Need ultrasonic)
Protocols
-
Ca2+ Staining Technique
Ca2+ staining is an experimental technique that utilizes specific fluorescent probes (such as Fluo-4 AM, Fura-2, etc.) to qualitatively or quantitatively detect dynamic changes in intracellular Ca2+ concentrations; this is achieved by monitoring the changes in fluorescent signals generated when these probes bind to free intracellular calcium ions. The underlying principle relies primarily on the presence of chelating groups within the probe's molecular structure that possess high affinity for calcium ions.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
-
Data Sheet (323 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
References
[2]. Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406(10520):2631-2643. [Content Brief]
[3]. Briere DA, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)